Vanderbilt Vaccine Center
Oct. 26, 2017—Researchers at Vanderbilt University Medical Center are leading an international effort to develop a universal influenza vaccine that would protect everyone against all strains of the flu anywhere in the world.
Apr. 11, 2017—The Human Vaccines Project and Vanderbilt University Medical Center (VUMC) announced this week that they joined forces with Illumina Inc. to decipher the human immunome, the genetic underpinnings of the immune system.
Apr. 5, 2017—The Vanderbilt Center for Structural Biology and the Vanderbilt Vaccine Center invite you to attend the 2017 Symposium on Modeling Immunity April 27. The event will focus on modeling and designing antibodies.
Mar. 30, 2017—The 2017 Vanderbilt Symposium on Modeling Immunity will be held from 1 to 4:30 p.m. Thursday, April 27, in room 1220 MRB III.
Feb. 23, 2017—James Crowe Jr., M.D., director of the Vanderbilt Vaccine Center, is the 2017-2018 recipient of the Samuel Rosenthal Prize for Excellence in Academic Pediatrics.
Feb. 9, 2017—Researchers at Vanderbilt University Medical Center (VUMC) have taken another step toward developing a vaccine against respiratory syncytial virus (RSV), the major cause of life-threatening pneumonia in infants worldwide.
Nov. 7, 2016—Researchers at Vanderbilt University Medical Center and Washington University School of Medicine in St. Louis have isolated a human monoclonal antibody that in a mouse model “markedly reduced” infection by the Zika virus.
Oct. 20, 2016—To prepare for the potential of a smallpox return, Vanderbilt researchers are isolating and studying naturally occurring antibodies from the blood of previously infected or immunized people.
Oct. 20, 2016—Respiratory syncytial virus (RSV) is the major cause of life-threatening viral pneumonia in infants worldwide, yet despite repeated efforts, scientists have been unable to develop an effective vaccine against it.
Sep. 28, 2016—New discoveries will guide efforts to develop vaccines or antiviral agents for norovirus, the most common cause of infectious diarrhea.
Sep. 8, 2016—A multi-center research team including scientists from the Vanderbilt Vaccine Center has come up with a clever “Trojan Horse” strategy for thwarting the highly lethal Ebola virus.
Aug. 11, 2016—Using an antibody generated at Vanderbilt University Medical Center that neutralizes the Ebola virus, researchers at the Scripps Research Institute in La Jolla, California, have determined the structure of a “decoy” protein that may enable the virus to evade detection by the immune system.